It is very important to know about what medicine is given by the doctor, for what condition, and when it needs to be taken in what dose. This information given by the doctor is called Prescription. The patients should be familiar with the medicine prescription, and the details about the medicine before purchasing it and using it. Some medications need not be prescribed by healthcare practitioners and can be purchased and used without prescription by the patients; these are called over-the-counter medications. Read the drug prescription information of Macrozit before taking it.
What is Macrozit
Macrozit is an antibiotic that fights bacteria. Macrozit is used to treat many different types of infections caused by bacteria, such as respiratory infections, skin infections, ear infections, and sexually transmitted diseases. Macrozit may also be used for purposes not listed in Macrozit guide.
Macrozit side effects
Get emergency medical help if you have any of these signs of an allergic reaction: hives; difficulty breathing; swelling of your face, lips, tongue, or throat. Call your doctor at once if you have:
diarrhea that is watery or bloody;
headache with chest pain and severe dizziness, fainting, fast or pounding heartbeats;
nausea, upper stomach pain, itching, loss of appetite, dark urine, clay-colored stools, jaundice (yellowing of the skin or eyes); or
severe skin reaction -- fever, sore throat, swelling in your face or tongue, burning in your eyes, skin pain, followed by a red or purple skin rash that spreads (especially in the face or upper body) and causes blistering and peeling.
Common side effects may include:
mild diarrhea;
mild stomach pain or upset;
dizziness; or
vaginal itching or discharge.
This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088. See also: Side effects (in more detail)
advertisement
Macrozit dosing
Usual Adult Dose for Mycoplasma Pneumonia:
Community-acquired pneumonia: Oral: Immediate-release: 500 mg orally as a single dose on the first day followed by 250 mg orally once a day on days 2 through 5 for mild infections Extended-release suspension: 2 g orally as a single dose for mild to moderate infections IV: 500 mg IV once a day for at least 2 days followed by 500 mg orally once a day to complete a 7- to 10-day course of therapy
Usual Adult Dose for Pneumonia:
Community-acquired pneumonia: Oral: Immediate-release: 500 mg orally as a single dose on the first day followed by 250 mg orally once a day on days 2 through 5 for mild infections Extended-release suspension: 2 g orally as a single dose for mild to moderate infections IV: 500 mg IV once a day for at least 2 days followed by 500 mg (immediate-release formulation) orally once a day to complete a 7- to 10-day course of therapy
Usual Adult Dose for Legionella Pneumonia:
Community-acquired pneumonia: 500 mg IV once a day for at least 2 days followed by 500 mg orally once a day to complete a 7- to 10-day course of therapy (Not approved by FDA) Legionnaires' disease: 500 mg IV or orally once a day Duration: 3 to 5 days for mild to moderate infections in immunocompetent patients; a longer treatment duration (at least 7 to 10 days or 3 weeks) may be necessary to prevent relapse in patients with more severe infections or with underlying comorbidity or immunodeficiency
Usual Adult Dose for Tonsillitis/Pharyngitis:
Immediate-release: 500 mg orally as a single dose on the first day followed by 250 mg orally once a day on days 2 through 5 Recommended as an alternative (second-line therapy) in patients who cannot use first-line therapy
Usual Adult Dose for Sinusitis:
Acute bacterial sinusitis: Immediate-release: 500 mg orally once a day for 3 days Extended-release suspension: 2 g orally as a single dose for mild to moderate infections
Usual Adult Dose for Skin and Structure Infection:
Uncomplicated: Immediate-release: 500 mg orally as a single dose on the first day followed by 250 mg orally once a day on days 2 through 5
Usual Adult Dose for Gonococcal Infection -- Uncomplicated:
Immediate-release: Gonococcal urethritis and cervicitis: 2 g orally as a single dose Centers for Disease Control and Prevention recommendations: Uncomplicated infections of the cervix, urethra, or rectum: Recommended regimen: 1 g orally as a single dose plus ceftriaxone Alternative regimens: If ceftriaxone is not available: 1 g orally as a single dose plus cefixime plus test-of-cure in 1 week If patient has severe cephalosporin allergy: 2 g orally as a single dose plus test-of-cure in 1 week Uncomplicated infections of the pharynx: Recommended regimen: 1 g orally as a single dose plus ceftriaxone The patient's sexual partner(s) should also be evaluated/treated.
Usual Adult Dose for Nongonococcal Urethritis:
Urethritis and cervicitis due to Chlamydia trachomatis: Immediate-release: 1 g orally as a single dose The patient's sexual partner(s) should also be evaluated/treated.
Usual Adult Dose for Chlamydia Infection:
Urethritis and cervicitis due to Chlamydia trachomatis: Immediate-release: 1 g orally as a single dose The patient's sexual partner should also be evaluated/treated.
Usual Adult Dose for Cervicitis:
Urethritis and cervicitis due to Chlamydia trachomatis: Immediate-release: 1 g orally as a single dose The patient's sexual partner(s) should also be evaluated/treated.
Usual Adult Dose for Chancroid:
Immediate-release: 1 g orally as a single dose The patient's sexual partner should also be evaluated/treated.
Usual Adult Dose for Pelvic Inflammatory Disease:
500 mg IV once a day for 1 or 2 days followed by 250 mg (immediate-release formulation) orally once a day to complete a 7-day course of therapy The patient's sexual partner(s) should also be evaluated/treated.
Usual Adult Dose for Chronic Obstructive Pulmonary Disease -- Acute:
Acute bacterial exacerbations of COPD : Immediate-release: 500 mg orally once a day for 3 days or 500 mg orally as a single dose on the first day followed by 250 mg orally once a day on days 2 through 5
Usual Adult Dose for Mycobacterium avium-intracellulare -- Prophylaxis:
Immediate-release: Prevention of disseminated Mycobacterium avium complex (MAC) disease in patients with advanced HIV infection: 1200 mg orally once a week; may be combined with the approved dosage regimen of rifabutin (Not approved by FDA) American Thoracic Society (ATS), CDC, National Institutes of Health (NIH), and Infectious Diseases Society of America (IDSA) recommendations for HIV-infected patients: Primary prevention of disseminated MAC disease: 1200 mg orally once a week Chronic maintenance therapy (secondary prophylaxis) for disseminated MAC disease: 500 to 600 mg orally once a day plus ethambutol, with or without rifabutin; recommended as an alternative regimen Secondary prophylaxis is usually continued for life; however, discontinuation may be considered in patients with sustained immune recovery in response to antiretroviral therapy.
Usual Adult Dose for Mycobacterium avium-intracellulare -- Treatment:
Immediate-release: Treatment of disseminated MAC infections in patients with advanced HIV infection: 600 mg orally once a day plus ethambutol Other antimycobacterial drugs with in vitro activity against MAC may be added to this regimen at the physician's discretion. ATS, CDC, NIH, and IDSA recommendations: Treatment of disseminated MAC infections in HIV-infected patients: 500 to 600 mg orally once a day plus ethambutol, with or without rifabutin; recommended as an alternative regimen Combination therapy with at least 2 drugs is recommended. Chronic suppressive therapy (secondary prophylaxis) is recommended after initial therapy.
Usual Adult Dose for Granuloma Inguinale:
(Not approved by FDA) CDC recommendations: Immediate-release: 1 g orally once a week for at least 3 weeks and until all lesions have completely healed This regimen is recommended as an alternative to doxycyline. The patient's sexual partner(s) should also be evaluated/treated.
Usual Adult Dose for STD Prophylaxis:
CDC recommendations for sexual assault victims: Immediate-release: 1 g orally as a single dose, in conjunction with metronidazole plus (ceftriaxone or cefixime)
Usual Adult Dose for Pertussis Prophylaxis:
(Not approved by FDA) CDC recommendations for treatment and postexposure prophylaxis: Immediate-release: 500 mg orally as a single dose on the first day followed by 250 mg orally once a day on days 2 through 5
Usual Adult Dose for Pertussis:
CDC recommendations for treatment and postexposure prophylaxis: Immediate-release: 500 mg orally as a single dose on the first day followed by 250 mg orally once a day on days 2 through 5
Usual Adult Dose for Lyme Disease -- Erythema Chronicum Migrans:
(Not approved by FDA) IDSA recommendations: Early localized or early disseminated Lyme disease associated with erythema migrans, in the absence of specific neurologic manifestations or advanced atrioventricular heart block: Immediate-release: 500 mg orally once a day for 7 to 10 days Macrozit is recommended when first-line agents (oral doxycycline, amoxicillin, or cefuroxime) cannot be used. Patients should be monitored closely to ensure resolution of clinical manifestations.
Usual Adult Dose for Babesiosis:
IDSA recommendations: Immediate-release: 500 to 1000 mg orally as a single dose on the first day followed by 250 mg orally once a day for a total of 7 to 10 days, in combination with atovaquone For immunocompromised patients, Macrozit 600 to 1000 mg orally per day may be used.
Usual Adult Dose for Bacterial Endocarditis Prophylaxis:
(Not approved by FDA) American Heart Association (AHA) recommendations for patients allergic to penicillins: Immediate-release: 500 mg orally as a single dose 30 to 60 minutes prior to the procedure
Usual Adult Dose for Toxoplasmosis:
CDC, NIH, and IDSA recommendations for HIV-infected patients: Immediate-release: 900 to 1200 mg orally once a day, in conjunction with pyrimethamine and leucovorin Duration: At least 6 weeks; longer duration if disease is extensive or response is incomplete at 6 weeks Macrozit is recommended as an alternative regimen.
Usual Adult Dose for Typhoid Fever:
(Not approved by FDA) Immediate-release: 1000 mg orally once a day for 5 days Alternatively, a dosage of 8 to 10 mg/kg (maximum: 500 mg/dose) orally once a day for 7 days has been recommended.
Usual Adult Dose for Upper Respiratory Tract Infection:
Immediate-release: 500 mg orally as a single dose on the first day followed by 250 mg orally once a day on days 2 through 5
Usual Adult Dose for Bronchitis:
(Not approved by FDA) Immediate-release: 500 mg orally as a single dose on the first day followed by 250 mg orally once a day on days 2 through 5
Usual Pediatric Dose for Otitis Media:
Acute: Immediate-release: 6 months or older: 30 mg/kg orally as a single dose or 10 mg/kg (maximum: 500 mg/dose) orally once a day for 3 days or 10 mg/kg (maximum: 500 mg/dose) orally as a single dose on the first day followed by 5 mg/kg (maximum: 250 mg/dose) orally once a day on days 2 thru 5
Usual Pediatric Dose for Mycoplasma Pneumonia:
Community-acquired pneumonia: Oral: Immediate-release: 6 months or older: 10 mg/kg (maximum: 500 mg/dose) orally as a single dose on the first day followed by 5 mg/kg (maximum: 250 mg/dose) orally once a day on days 2 thru 5 16 years or older: 500 mg orally as a single dose on the first day followed by 250 mg orally once a day on days 2 through 5 for mild infections Extended-release suspension: 6 months or older: Less than 34 kg: 60 mg/kg orally as a single dose for mild to moderate infections 34 kg or more: 2 g orally as a single dose for mild to moderate infections 16 years or older: 2 g orally as a single dose for mild to moderate infections IV: 16 years or older: 500 mg IV once a day for at least 2 days followed by 500 mg (immediate-release formulation) orally once a day to complete a 7- to 10-day course of therapy
Usual Pediatric Dose for Pneumonia:
Community-acquired pneumonia: Oral: Immediate-release: 6 months or older: 10 mg/kg orally as a single dose on the first day followed by 5 mg/kg (maximum: 250 mg/dose) orally once a day on days 2 thru 5 16 years or older: 500 mg orally as a single dose on the first day followed by 250 mg orally once a day on days 2 through 5 for mild infections Extended-release suspension: 6 months or older: Less than 34 kg: 60 mg/kg orally as a single dose for mild to moderate infections 34 kg or more: 2 g orally as a single dose for mild to moderate infections 16 years or older: 2 g orally as a single dose for mild to moderate infections IV: 16 years or older: 500 mg IV once a day for at least 2 days followed by 500 mg (immediate-release formulation) orally once a day to complete a 7- to 10-day course of therapy
Usual Pediatric Dose for Legionella Pneumonia:
Community-acquired pneumonia: 16 years or older: 500 mg IV once a day for at least 2 days followed by 500 mg (immediate-release formulation) orally once a day to complete a 7- to 10-day course of therapy
Usual Pediatric Dose for Tonsillitis/Pharyngitis:
Immediate-release: 2 years or older: 12 mg/kg orally once a day for 5 days 16 years or older: 500 mg orally as a single dose on the first day followed by 250 mg orally once a day on days 2 through 5 Recommended as an alternative (second-line therapy) in patients who cannot use first-line therapy
Usual Pediatric Dose for Sinusitis:
Acute bacterial sinusitis: Immediate-release: 6 months or older: 10 mg/kg (maximum: 500 mg/dose) orally once a day for 3 days 16 years or older: 500 mg orally once a day for 3 days Extended-release suspension: 16 years or older: 2 g orally as a single dose for mild to moderate infections
Usual Pediatric Dose for Skin and Structure Infection:
Uncomplicated: Immediate-release: 16 years or older: 500 mg orally as a single dose on the first day followed by 250 mg orally once a day on days 2 through 5
Usual Pediatric Dose for Gonococcal Infection -- Uncomplicated:
Immediate-release: Gonococcal urethritis and cervicitis: 16 years or older: 2 g orally as a single dose CDC recommendations for children weighing greater than 45 kg and adolescents: Uncomplicated infections of the cervix, urethra, or rectum: Recommended regimen: 1 g orally as a single dose plus ceftriaxone Alternative regimens: If ceftriaxone is not available: 1 g orally as a single dose plus cefixime plus test-of-cure in 1 week If patient has severe cephalosporin allergy: 2 g orally as a single dose plus test-of-cure in 1 week Uncomplicated infections of the pharynx: Recommended regimen: 1 g orally as a single dose plus ceftriaxone The patient's sexual partner(s) should also be evaluated/treated.
Usual Pediatric Dose for Nongonococcal Urethritis:
Immediate-release: Urethritis and cervicitis due to C trachomatis: 16 years or older: 1 g orally as a single dose (Not approved by FDA) CDC recommendations: Children less than 8 years who weigh 45 kg or more, children 8 years or older, and adolescents: 1 g orally as a single dose The patient's sexual partner(s) should also be evaluated/treated.
Usual Pediatric Dose for Chlamydia Infection:
Immediate-release: Urethritis and cervicitis due to C trachomatis: 16 years or older: 1 g orally as a single dose CDC recommendations: Children less than 8 years who weigh 45 kg or more, children 8 years or older, and adolescents: 1 g orally as a single dose The patient's sexual partner(s) should also be evaluated/treated.
Usual Pediatric Dose for Cervicitis:
Immediate-release: Urethritis and cervicitis due to C trachomatis: 16 years or older: 1 g orally as a single dose (Not approved by FDA) CDC recommendations: Children less than 8 years who weigh 45 kg or more, children 8 years or older, and adolescents: 1 g orally as a single dose The patient's sexual partner(s) should also be evaluated/treated.
Usual Pediatric Dose for Chancroid:
Immediate-release: 16 years or older: 1 g orally as a single dose American Academy of Pediatrics (AAP) recommendations: Infants and children weighing less than 45 kg: 20 mg/kg (maximum: 1 g/dose) orally as a single dose Children weighing 45 kg or more and adolescents: 1 g orally as a single dose The patient's sexual partner(s) should also be evaluated/treated.
Usual Pediatric Dose for Pelvic Inflammatory Disease:
16 years or older: 500 mg IV once a day for 1 or 2 days followed by 250 mg (immediate-release formulation) orally once a day to complete a 7-day course of therapy The patient's sexual partner(s) should also be evaluated/treated.
Usual Pediatric Dose for Chronic Obstructive Pulmonary Disease -- Acute:
Acute bacterial exacerbations of COPD : Immediate-release: 16 years or older: 500 mg orally once a day for 3 days or 500 mg orally as a single dose on the first day followed by 250 mg orally once a day on days 2 through 5
Usual Pediatric Dose for Mycobacterium avium-intracellulare -- Prophylaxis:
Immediate-release: Prevention of disseminated MAC disease in patients with advanced HIV infection: 16 years or older: 1200 mg orally once a week; may be combined with the approved dosage regimen of rifabutin (Not approved by FDA) ATS, CDC, NIH, IDSA, and AAP recommendations for HIV-exposed and HIV-infected infants and children: Primary prevention of MAC infections: Preferred regimen: 20 mg/kg (maximum: 1200 mg/dose) orally once a week Alternative regimen: 5 mg/kg (maximum: 250 mg/dose) orally once a day Secondary prevention of MAC infections: 5 mg/kg (maximum: 250 mg/dose) orally once a day plus ethambutol, with or without rifabutin; recommended as an alternative regimen ATS, CDC, NIH, and IDSA recommendations for HIV-infected adolescents: Primary prevention of disseminated MAC disease: 1200 mg orally once a week Chronic maintenance therapy (secondary prophylaxis) for disseminated MAC disease: 500 to 600 mg orally once a day plus ethambutol, with or without rifabutin; recommended as alternative therapy Secondary prophylaxis is usually continued for life; however, discontinuation may be considered in patients with sustained immune recovery in response to antiretroviral therapy.
Usual Pediatric Dose for Mycobacterium avium-intracellulare -- Treatment:
Immediate-release: Treatment of disseminated MAC infections in patients with advanced HIV infection: 16 years or older: 600 mg orally once a day plus ethambutol Other antimycobacterial drugs with in vitro activity against MAC may be added to this regimen at the physician's discretion. ATS, CDC, NIH, IDSA, and AAP recommendations for HIV-exposed and HIV-infected infants and children: Treatment of MAC infections: 10 to 12 mg/kg (maximum: 500 mg/dose) orally once a day plus ethambutol, with or without rifabutin; recommended as an alternative regimen ATS, CDC, NIH, and IDSA recommendations for HIV-infected adolescents: Treatment of disseminated MAC infections: 500 to 600 mg orally once a day plus ethambutol, with or without rifabutin; recommended as an alternative regimen Combination therapy with at least 2 drugs is recommended. Chronic suppressive therapy (secondary prophylaxis) is recommended after initial therapy.
Usual Pediatric Dose for STD Prophylaxis:
(Not approved by FDA) CDC recommendations for adolescent sexual assault victims: Immediate-release: 1 g orally as a single dose, in conjunction with metronidazole plus (ceftriaxone or cefixime)
Usual Pediatric Dose for Pertussis Prophylaxis:
CDC recommendations for treatment and postexposure prophylaxis: Immediate-release: Less than 1 month: 10 mg/kg orally once a day for 5 days 1 to 5 months: 10 mg/kg orally once a day for 5 days 6 months or older: 10 mg/kg (maximum: 500 mg/dose) orally as a single dose on the first day followed by 5 mg/kg (maximum: 250 mg/dose) orally once a day on days 2 thru 5
Usual Pediatric Dose for Pertussis:
(Not approved by FDA) CDC recommendations for treatment and postexposure prophylaxis: Immediate-release: Less than 1 month: 10 mg/kg orally once a day for 5 days 1 to 5 months: 10 mg/kg orally once a day for 5 days 6 months or older: 10 mg/kg (maximum: 500 mg/dose) orally as a single dose on the first day followed by 5 mg/kg (maximum: 250 mg/dose) orally once a day on days 2 thru 5
Usual Pediatric Dose for Lyme Disease -- Erythema Chronicum Migrans:
IDSA recommendations for children: Early localized or early disseminated Lyme disease associated with erythema migrans, in the absence of specific neurologic manifestations or advanced atrioventricular heart block: Immediate-release: 10 mg/kg (maximum: 500 mg/dose) orally once a day for 7 to 10 days Macrozit is recommended when first-line agents (oral doxycycline, amoxicillin, or cefuroxime) cannot be used. Patients should be monitored closely to ensure resolution of clinical manifestations.
Usual Pediatric Dose for Babesiosis:
(Not approved by FDA) Immediate-release: IDSA recommendations for children: 10 mg/kg (maximum: 500 mg/dose) orally as a single dose on the first day followed by 5 mg/kg (maximum: 250 mg/dose) orally once a day for a total of 7 to 10 days, in combination with atovaquone Alternatively, a dosage of 12 mg/kg (maximum: 600 mg/dose) orally once a day for 7 to 10 days in combination with atovaquone has been recommended for pediatric patients.
Usual Pediatric Dose for Bacterial Endocarditis Prophylaxis:
AHA recommendations for children allergic to penicillins: Immediate-release: 15 mg/kg (maximum: 500 mg) orally as a single dose 30 to 60 minutes prior to procedure
Usual Pediatric Dose for Toxoplasmosis:
(Not approved by FDA) CDC, NIH, and IDSA recommendations for HIV-infected adolescents: Immediate-release: 900 to 1200 mg orally once a day, in conjunction with pyrimethamine and leucovorin Duration: At least 6 weeks; longer duration if disease is extensive or response is incomplete at 6 weeks Macrozit is recommended as an alternative regimen.
Usual Pediatric Dose for Typhoid Fever:
Immediate-release: 3 years or older: 20 mg/kg (maximum: 1 g/dose) orally once a day for 5 to 7 days Alternatively, a dosage of 10 mg/kg (maximum: 500 mg/dose) orally once a day for 7 days has been recommended.
Usual Pediatric Dose for Cystic Fibrosis:
(Not approved by FDA) Chronic Pseudomonas aeruginosa infections in CF patients: 6 years or older, weight 25 kg or more and adolescents: 25 to less than 40 kg: 250 mg orally on Mondays, Wednesdays, Fridays 40 kg or more: 500 mg orally on Mondays, Wednesdays, Fridays If side effects are intolerable, the dose should be decreased to twice a week, or if necessary, once a week.
Usual Pediatric Dose for Upper Respiratory Tract Infection:
Immediate-release: 6 months or older: 10 mg/kg (maximum: 500 mg/dose) orally as a single dose on the first day followed by 5 mg/kg (maximum: 250 mg/dose) orally once a day on days 2 thru 5
Generic drug is the basic drug with an active substance in it, and the name of the generic drug is same as active substance most of the times. Like Acetaminophen/Paracetemol is Generic name and it has different brand names like Tylenol, Acimol, Crocin, Calpol etc. All these Brand names contain the same Paracetemol, but the medications are manufactured by different companies, so the different brand names. Generic drug is always cheaper and affordable, and it can be replaced in place of brand name drug prescribed by the healthcare practitioner. The Generic medicine has same properties as branded medicine in terms of uses, indications, doses, side effects, so no need to worry on that. Just select the most affordable generic or branded medicine.
Dailymed."Azithromycin: dailymed provides trustworthy information about marketed drugs in the united states. dailymed is the official provider of fda label information (package inserts).". https://dailymed.nlm.nih.gov/dailym... (accessed August 28, 2018).
Can Macrozit be stopped immediately or do I have to stop the consumption gradually to ween off?
In some cases, it always advisable to stop the intake of some medicines gradually because of the rebound effect of the medicine.
It's wise to get in touch with your doctor as a professional advice is needed in this case regarding your health, medications and further recommendation to give you a stable health condition.
What other drugs will affect Macrozit?
Many drugs can interact with Macrozit. Not all possible interactions are listed here. Tell your doctor about all your medications and any you start or stop using during treatment with Macrozit, especially:
droperidol;
methadone;
nelfinavir;
another antibiotic--clarithromycin, erythromycin, moxifloxacin, pentamidine;
medicine to treat a psychiatric disorder--chlorpromazine, haloperidol, mesoridazine, pimozide, thioridazine.
This list is not complete and many other drugs can interact with Macrozit. This includes prescription and over-the-counter medicines, vitamins, and herbal products. Give a list of all your medicines to any healthcare provider who treats you.
Who should not take Macrozit?
You should not use this medication if you have ever had jaundice or liver problems caused by taking Macrozit. You should not use Macrozit if you are allergic to it or to similar drugs such as clarithromycin, erythromycin, or telithromycin.
To make sure Macrozit is safe for you, tell your doctor if you have:
liver disease;
kidney disease;
myasthenia gravis;
a heart rhythm disorder; or
a history of Long QT syndrome.
FDA pregnancy category B. This medication is not expected to be harmful to an unborn baby. Tell your doctor if you are pregnant or plan to become pregnant during treatment.
It is not known whether Macrozit passes into breast milk or if it could harm a nursing baby. Tell your doctor if you are breast-feeding a baby.
Do not give this medicine to a child younger than 6 months old.
Older adults may be more likely to have side effects on heart rhythm, including a life-threatening fast heart rate.
How should I take Macrozit?
Follow all directions on your prescription label. Do not take this medicine in larger or smaller amounts or for longer than recommended. The dose and length of treatment with Macrozit may not be the same for every type of infection.
You may take most forms of Macrozit with or without food.
Take Macrozit extended release liquid on an empty stomach, at least 1 hour before or 2 hours after a meal.
To use the oral suspension single dose packet: Open the packet and pour the medicine into 2 ounces of water. Stir this mixture and drink all of it right away. Do not save for later use. To make sure you get the entire dose, add a little more water to the same glass, swirl gently and drink right away.
Throw away any mixed Macrozit oral suspension that has not been used within 12 hours.
Shake the oral suspension (liquid) well just before you measure a dose. Measure the liquid with a special dose-measuring spoon or medicine cup. If you do not have a dose-measuring device, ask your pharmacist for one.
Use this medication for the full prescribed length of time. Your symptoms may improve before the infection is completely cleared. Skipping doses may also increase your risk of further infection that is resistant to antibiotics. Macrozit will not treat a viral infection such as the common cold or flu.
Store at room temperature away from moisture and heat. Throw away any unused liquid medicine after 10 days.
Can Macrozit be taken or consumed while pregnant?
Please visit your doctor for a recommendation as such case requires special attention.
Can Macrozit be taken for nursing mothers or during breastfeeding?
Kindly explain your state and condition to your doctor and seek medical advice from an expert.
advertisement
Reviews
Following the study conducted by gmedication.com on Macrozit, the result is highlighted below. However, it must be clearly stated that the survey and result is based solely on the perception and impression of visitors and users of the website as well as consumers of Macrozit. We, therefore, urge readers not to base their medical judgment strictly on the result of this study but on test/diagnosis duly conducted by a certified medical practitioners or physician.
Patient reports
Patient reported useful
No survey data has been collected yet
One patient reported side effects
Does the Macrozit Have Any Side Effects? Based on the survey report from users of gmedication.com, about No side effects number of people suffered some side effect after consumption of Macrozit. All drugs have a portion of undesirable side effects. These effects could be irritations too insignificant for the patient to even notice. However, the side effects of drugs may be determined by several factors like severity of disease and conditions associated with individual patients. However, one of the biggest factors is the dosage consumed. The higher the quantity taken by an individual, the greater the healing effect and the corresponding side effect. All patients have their different intensity of side effects. Ensure you consult your health care provider immediately you notice an unusual side effect affect the consumption of Macrozit.
Patients
%
No side effects
1
100.0%
Patient reported price estimates
No survey data has been collected yet
Four patients reported frequency of use
How often should I take Macrozit? According to the survey, gmedication.com reported that users of Macrozit should take Twice in a day as the primarily recommended frequency. However, patients are advised to follow the dosage as prescribed by their physician religiously. To get the opinions of other patients on the ideal consumption frequency of the medicine, click here.
Patients
%
Twice in a day
2
50.0%
Once in a day
2
50.0%
21 patients reported doses
What is the specific doses you have used? Macrozit May come in various doses. In most cases, antibiotics, antihypertensive, pain killers and anti-diabetic drugs available in different doses. Your doctor may prescribe any of the doses based on the severity of the patient's condition. According to our reports, users of gmedication.com used the drugs in the following dosage percentage (Provide dosage percentage). Only a handful of drugs are made in a single or fixed dose. Regular health conditions like fever have similar doses. For instance [acetaminophen, 500mg] was used by the patients surveyed although it comes in different doses.
Patients
%
201-500mg
16
76.2%
501mg-1g
4
19.0%
51-100mg
1
4.8%
Four patients reported time for results
How long will I use Macrozit before I begin to notice the effect? According to the report by users of gmedication.com, about 3 days and a few days was the most common time duration among the participants, before they began to feel relief in their health conditions. It is noteworthy that you may not get the same result with other users within the same time frame. Several factors determine the timeframe; hence we implore you to consult your medical expert to get professional advice on how long you should expect to see improvement while consuming Macrozit. However, if you wish to get the response of other users on the time effectiveness of using Macrozit kindly click here
Patients
%
3 days
3
75.0%
5 days
1
25.0%
Patient reported administration
No survey data has been collected yet
Sixteen patients reported age
Patients
%
16-29
4
25.0%
30-45
3
18.8%
46-60
2
12.5%
1-5
2
12.5%
> 60
2
12.5%
6-15
2
12.5%
< 1
1
6.2%
Patient reviews
There are no reviews yet. Be the first to write one!